Compare CABA & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | ELME |
|---|---|---|
| Founded | 2017 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 198.2M |
| IPO Year | 2019 | N/A |
| Metric | CABA | ELME |
|---|---|---|
| Price | $2.31 | $2.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $14.57 | $14.25 |
| AVG Volume (30 Days) | 4.2M | ★ 9.5M |
| Earning Date | 11-10-2025 | 02-20-2026 |
| Dividend Yield | N/A | ★ 33.03% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $246,959,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.10 |
| 52 Week Low | $0.99 | $2.10 |
| 52 Week High | $3.67 | $18.08 |
| Indicator | CABA | ELME |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 7.34 |
| Support Level | $2.42 | $2.17 |
| Resistance Level | $2.61 | $3.11 |
| Average True Range (ATR) | 0.25 | 0.10 |
| MACD | -0.03 | 0.40 |
| Stochastic Oscillator | 20.38 | 8.80 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.